{"entity":{"id":"nct07814417","kind":"trial","name":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation","aka":[],"tldr":"A phase 2 trial of olomorasib, cetuximab, fOLFOX (5-FU, leucovorin, oxaliplatin) and fluorouracil (5-FU) in colorectal cancer, run by Eli Lilly and Company, not yet recruiting.","summary":"A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation is a phase 2, interventional study registered as NCT07814417 by Eli Lilly and Company, with a registry enrolment figure of 50 participants, started 2026-10 and due to reach its primary completion in 2028-11. Interventions recorded: Olomorasib; Cetuximab; Oxaliplatin; Leucovorin/levofolinate calcium; 5-fluorouracil. Conditions listed: Colorectal Neoplasms. Primary outcome: Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; Progression-Free Survival (PFS) Per RECIST v1.1. Colorectal eligibility wording from the registry: \"* Histologically or cytologically confirmed colorectal cancer (CRC) with Stage III or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07814417","url":"https://clinicaltrials.gov/study/NCT07814417"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer","kras-g12c-colorectal"],"sections":[],"technologies":["cytotoxic-chemotherapy","kras-inhibitors","monoclonal-antibody","platinum"],"targets":[],"drugs":["olomorasib","cetuximab","folfox","fluorouracil"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07814417","phase":"2","setting":"A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Olomorasib in Combination With Cetuximab and mFOLFOX6 in Participants With KRAS G12C-Mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer","sponsor":"Eli Lilly and Company","enrolled":50,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07814417/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"kras-g12c-colorectal","kind":"cancer","name":"KRAS G12C-mutant colorectal cancer","route":"/cancers/kras-g12c-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cetuximab","kind":"drug","name":"Cetuximab","route":"/drugs/cetuximab/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"olomorasib","kind":"drug","name":"Olomorasib","route":"/drugs/olomorasib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}